Methotrexate is often used in patients with systemic lupus erythematosus for effective disease controlsand steroid-sparing, and has been known to involve the development of lymphoproliferative disorders for patients with autoimmune diseases. We report a case of spontaneous regression of Epstein-Barr virus-positive methotrexate-associated Hodgkin's lymphoma in a 24-year-old woman with systemic lupus erythematosus. Following 6 months of treatment with low-dose methotrexate, the patient developed a neck mass in the right submandibular area. A computed tomography scan of the neck, chest and abdomen revealed multiple enlarged lymph nodes. Excisional biopsy of the neck masses confirmed infiltrations of malignant lymphoid cells that were positive for CD15, CD30, and Epstein-Barr virus-encoded RNA. Reduction of the mass was observed 3 weeks after withdrawing from the methotrexate treatment. At 7 months after initial presentation, computed tomography revealed near-complete regression of lymphadenopathy. After 30 months, the patient was still in complete clinical remission.
Introduction
Methotrexate (MTX), an inhibitor of dihydrofolate reductase, is mainly administered to patients with autoimmune diseases such as rheumatoid arthritis to suppress the exaggerated immune response. Less commonly, MTX is used in patients with systemic lupus erythematosus (SLE) to reduce daily glucocorticoid dose and aid in controlling arthritis and skin manifestations (1, 2) . Recent reports have suggested that development of lymphoproliferative disorders or lymphomas in patients with autoimmune diseases is associated with receiving MTX (3, 4) . Although the true contribution of MTX to the pathogenesis of lymphoproliferative disorders remains unknown, its clinical relevance requires particular attention to the patients taking MTX and careful management of lymphoproliferative disorders or lymphomas when they occur.
Unlike in rheumatoid arthritis, few cases describe spontaneous remission of Hodgkin's lymphoma following withdrawal of methotrexate in a patient with SLE. Here we report a case of development of Hodgkin's lymphoma (HL) in a patient with SLE receiving MTX and spontaneous regression only after discontinuation of MTX.
Case Report
A 24-year-old female with SLE presented with a right submandibular mass, that had been gradually enlarging over since 3 months ago. The mass was fixed, firm and tender. The patient also complained of fever (measured up to 38.0 o C), and night sweating, and weight loss of 2 kg over a month. A diagnosis of SLE had been made 9 years earlier on the basis of fever, malar rash, vasculitis of the central nervous system, leukopenia, thrombocytopenia, and positivity for anti-nuclear (ANA), anti-double strand DNA (dsDNA), and antiphospho- The patient in this case report had also taken MMF, which is reported to be associated with development of non-Hodgkin's lymphoma in a transplant population (16) . However, this association was not confirmed in a recent large-scale prospective study of renal transplant patients treated with MMF (17) . The association has not been described clearly in patients with SLE taking MMF alone or in combination with corticosteroids.
Three cases of lymphoma in SLE patients who had been taking MMF for lupus nephritis have been reported to date (18) (19) (20) .
All were primary lymphomas of the central nervous system (PCNSL), which is known to be a complication of systemic immunosuppression following organ transplantation and HIV infection (20) . After discontinuation of MMF, two patients underwent chemotherapy and one died from cerebellar hemorrhage complicated by brain biopsy. Therefore, MMF might foster an immunosuppressive environment that make a patient vulnerable to development of PCNSL. However, the association of MMF with PCNSL remains unclear in patients with lupus nephritis.
Summary
MTX is often used to lower the daily steroid dose in SLE patients with moderate disease activity, although it does not confer a significant advantage in decreasing disease activity 
